Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 25 clinical trials
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

Evaluates the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.

advanced solid tumor
solid tumor
malignant solid tumor
  • 08 Mar, 2021
  • 67 locations
An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR a HER2 or a HER3 Mutation

Objective(s):To investigate the efficacy and safety of afatinib in EGFR, HER 2 and HER3 mutated cancers, regardless of cancer type, excluding EGFR mutated non-small cell lung cancer.

  • 22 Jan, 2021
  • 5 locations
Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer

This is a single arm open-label multi-center phase II study, investigating disease control rate after 18 weeks of treatment with afatinib/cetuximab combination therapy in patients with advanced

measurable disease
epidermal growth factor
lung carcinoma
platelet count
  • 28 Jan, 2021
  • 4 locations
Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

immune checkpoint inhibitor. The primary objective is to evaluate the efficacy of the combination of cetuximab and afatinib.

  • 15 May, 2021
  • 1 location
Afatinib in Advanced Refractory Urothelial Cancer

This phase II trial studies how well afatinib dimaleate works in treating patients with urothelial cancer that cannot be removed surgically and has grown after treatment with standard first-line

spiral computed tomography
measurable disease
systemic chemotherapy
metastatic urothelial carcinoma
  • 26 Jan, 2021
  • 4 locations
Afatinib in Locally Advanced and Metastatic Chordoma

In this phase 2, single arm trial patients with locally advanced or metastatic, pathologically proven, EGFR expressing chordoma will be treated with afatinib. Two cohorts of patients will be

neutrophil count
absolute neutrophil count
renal function
gilbert's disease
  • 16 Jun, 2021
  • 3 locations
Afatinib With CT and RT for EGFR-Mutant NSCLC

tyrosine kinase inhibitor (TKI) can help increase the response to treatment. Afatinib is a tyrosine kinase inhibitor. It has been studied in a previous research study in participants with more

measurable disease
epidermal growth factor
lung carcinoma
stage iiia non-small cell lung cancer
  • 24 Jan, 2021
Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity

To assess if targeting activating EGFR and HER2 mutations in Non-Small Cell Lung Cancer (NSCLC) is more effective when these mutations are truncal dominant mutations (50%), as opposed to non-dominant (5 to <50%) or low frequency mutations (<5%). This trial will be available to patients registered to the TRACERx study …

measurable disease
lung carcinoma
neutrophil count
  • 25 Jan, 2021
  • 7 locations
Effect of Zanthoxylum Nitidum Tincture for Paronychia Caused by Afatinib

This is a randomized control trial evaluating the efficacy of zanthoxylum nitidum tincture on preventing progression of paronychia caused by afatinib from grade 1 to grade 2/3. Enrolled

  • 24 Jan, 2021
  • 1 location
Neoadjuvant Afatinib Therapy for Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

approved afatinib for first-line treatment of patients with metastatic NSCLC who have sensitizing EGFR mutations.The treatment of stage III NSCLC remains a matter of debate. Current multimodality treatment

  • 29 Jan, 2021
  • 1 location